NASDAQ:ASLN ASLAN Pharmaceuticals (ASLN) Stock Price, News & Analysis $0.60 0.00 (0.00%) As of 05/14/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock About ASLAN Pharmaceuticals Stock (NASDAQ:ASLN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ASLAN Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.60▼$0.6050-Day Range$0.60▼$0.6052-Week Range$0.48▼$25.44VolumeN/AAverage Volume122,322 shsMarket Capitalization$1.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ASLAN Pharmaceuticals Ltd is a clinical‐stage biotechnology company focused on the discovery and development of novel immunology and oncology therapies. The company leverages proprietary antibody and small‐molecule platforms to address critical biological targets involved in tumor immune evasion and inflammatory disease pathways. ASLAN’s R&D approach combines modern protein engineering, antibody-drug conjugates and precision small‐molecule design to generate next‐generation therapeutics. The company’s lead clinical programs include ASLAN003, an orally available allosteric IRAK4 inhibitor designed to modulate innate immune signaling in severe inflammatory diseases, and ASLAN004, a high-affinity nanobody targeting the CD39 ectonucleotidase to reinvigorate anti-tumor immune responses. In addition to these assets, ASLAN is advancing a diversified preclinical pipeline that features antibody-drug conjugates for solid tumors and multi-specific antibody formats aimed at difficult-to-treat cancers. Founded in Singapore in 2015, ASLAN has established operations across Asia, Australia and the United States to support global clinical development. The company completed its initial public offering on the Nasdaq in 2020 and maintains a management team with extensive leadership experience in biopharmaceutical research, regulatory affairs and commercial strategy. ASLAN continues to pursue strategic partnerships and clinical collaborations to accelerate its programs toward regulatory milestones and potential market authorization.AI Generated. May Contain Errors. Read More Receive ASLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ASLAN Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASLN Stock News HeadlinesPublic Health News | Today's Latest Stories | ReutersOctober 3, 2024 | reuters.comASLAN stock tumbles 54% after board votes to liquidateJuly 19, 2024 | msn.comYou're not getting into the SpaceX IPO. Do this instead.The SpaceX IPO is expected to price at $1.75 trillion - and retail investors won't get an allocation. Banks and insiders have already locked it up. But there is one small, publicly traded company that builds the critical infrastructure SpaceX cannot operate without. Dylan Jovine is releasing the ticker name today at no cost. | Behind the Markets (Ad)Why ASLAN Pharmaceuticals (ASLN) Shares Are Down 40%July 19, 2024 | msn.comWhy ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionJuly 19, 2024 | msn.comASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary LiquidationJuly 17, 2024 | globenewswire.comASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to AppealJuly 15, 2024 | globenewswire.comASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International ConferenceMay 21, 2024 | globenewswire.comSee More Headlines ASLN Stock Analysis - Frequently Asked Questions How have ASLN shares performed this year? ASLAN Pharmaceuticals' stock was trading at $0.60 on January 1st, 2026. Since then, ASLN shares have increased by 0.0% and is now trading at $0.60. How were ASLAN Pharmaceuticals' earnings last quarter? ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) issued its quarterly earnings results on Friday, August, 11th. The company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($6.40) by $5.52. The company had revenue of $12 million for the quarter. When did ASLAN Pharmaceuticals' stock split? Shares of ASLAN Pharmaceuticals reverse split on Wednesday, July 3rd 2024.The 1-8 reverse split was announced on Wednesday, July 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did ASLAN Pharmaceuticals IPO? ASLAN Pharmaceuticals (ASLN) raised $60 million in an initial public offering on Friday, May 4th 2018. The company issued 7,500,000 shares at $8.05 per share. Leerink Partners and Piper Jaffray served as the underwriters for the IPO and BTIG, H.C. Wainwright and CLSA were co-managers. How do I buy shares of ASLAN Pharmaceuticals? Shares of ASLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ASLAN Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ASLAN Pharmaceuticals investors own include Tesla (TSLA), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Meta Platforms (META), Zoom Communications (ZM), Fulgent Genetics (FLGT) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings8/11/2023Today5/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASLN CIK1722926 Webwww.aslanpharma.com Phone65-6817-9598Fax65-6225-2419Employees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)($21.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$44.22 million Net MarginsN/A Pretax Margin-290.83% Return on Equity-8,454.87% Return on Assets-121.60% Debt Debt-to-Equity RatioN/A Current Ratio1.05 Quick Ratio1.05 Sales & Book Value Annual Sales$12 million Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value($6.50) per share Price / Book-0.09Miscellaneous Outstanding Shares2,044,000Free Float1,948,000Market Cap$1.23 million OptionableNo Data Beta1.40 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ASLN) was last updated on 5/16/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredSecret behind near perfectly timed stock trades…?After 20 years of professional trading, Ross Givens says this is the single most lucrative market strategy he ...Traders Agency | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ASLAN Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ASLAN Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
